Copyright
©The Author(s) 2017.
World J Hepatol. Apr 18, 2017; 9(11): 544-550
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Table 2 Virologic outcomes
| Parameter | Elderly patients, n = 56 | Non-elderly patients, n = 141 | P |
| SVR24 | 51 (91.1) | 127 (90.1) | |
| Viral breakthrough | 1 (1.8) | 5 (3.5) | 0.519 |
| Post-treatment relapse | 2 (3.6) | 7 (5.0) | 0.675 |
| Ratio of patients who achieved SVR24 in the discontinued cases due to side effects | 5/7 (71.4) | 7/9 (77.8) |
- Citation: Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol 2017; 9(11): 544-550
- URL: https://www.wjgnet.com/1948-5182/full/v9/i11/544.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i11.544